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Abstract 
Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treat-
ment of vitreomacular traction (VMT). Materials and Methods: An 81-year-old man with VMT 
associated with central retinal vein occlusion in his left eye, was treated with a single intravitreal 
injection of ocriplasmin (25 μg). Best corrected visual acuity (BCVA), ocular fundus, and optical 
coherence tomography were examined before and after treatment. Results: Complete release 
of VMT produced a reduction of central macular thickness, ranging from 459 to 141 μm. BCVA 
remained stable. Discussion and Conclusions: The use of ocriplasmin was effective in the 
treatment of VMT. Ocriplasmin represents a valid alternative to conventional pars plana vitrec-
tomy. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Vitreomacular traction (VMT) is a complication of posterior vitreous detachment (PVD) 
characterized by distortion of the retinal profile, resulting in metamorphopsia and visual loss. 
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The vitreous gel undergoes degenerative processes such as synchysis (liquefaction and for-
mation of so-called lacunae) and syneresis (total collapse of the collagen fibers) which, to-
gether with the reduction of its water content, play an important role in determining the de-
tachment of the posterior hyaloid from the retinal surface. Adapted from Uchino et al. [1] and 
Johnson [2], four stages of PVD have been identified. Focal perifoveal PVD occurs in around 
50% at ages 30–39 years, whereas complete PVD is observed in 50% or more of individuals 
aged 70 years or older [3]. The main causes include: trauma, refractive errors (particularly 
myopia), surgery, inflammatory processes, and decreased estrogen levels in postmenopausal 
women. The process is usually asymptomatic; in a few cases, it may be complicated by vitre-
omacular adhesion (VMA) between the vitreous cortex and the macular area. VMA is the per-
sistent attachment of the posterior hyaloid to the macula during the formation of a partial 
PVD. It may produce tractional forces that lead to a spectrum of disorders, such as VMT syn-
drome and full-thickness macular hole [4]. Various factors may affect the development or  
severity of the disease: vitreous liquefaction and anatomical focal factors that may increase 
foveal adhesion and integrity of internal limiting membrane (ILM). Therefore, VMT has been 
associated with other conditions such as exudative age-related macular degeneration 
(ARMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and epiretinal mem-
brane (ERM). It may exacerbate cystoid macular edema associated with ERM, RVO, and dia-
betic retinopathy [5, 6]. Simple (noncontractile) ERM is associated with retinal surface wrin-
kling or “cellophane” maculopathy. However, the contraction of myofibroblasts within the 
more complex type of ERM has been proposed to exert a tangential traction at the vitreoretinal 
interface (VRI), which can result in retinal puckering, thickening, folding, or detachment, to-
gether with vascular distortion. An enzyme which acts against molecular substrates respon-
sible for VMA has been successfully used to induce vitreolysis. Plasmin and a truncated form 
of plasmin, ocriplasmin (formerly microplasmin), have been shown to be effective in ex vivo 
studies of vitreolysis both in animals and in humans. Ocriplasmin is a recombinant serine pro-
tease with activity against fibronectin and laminin, components of the VRI. Clinical studies 
suggested the role in inducing liquefaction of the vitreous and the consequent separation from 
the retina. For this purpose, an intravitreal injection of ocriplasmin (JETREA®), as nonsurgical 
treatment of VMT, was performed. The advent of optical coherence tomography (OCT) has 
proved a great benefit to the study of anatomy and disorders of the VRI. Spectral domain  
(SD)-OCT or time domain-OCT have similar ability to assess VRI abnormalities and outcomes 
of enzymatic vitreolysis. SD-OCT may be superior to formal clinical trial grading due to great-
er interreader reproducibility and, therefore, decreased need for arbitration of discrepant val-
ues [7]. 
Case Report 
An 81-year-old man, affected by arterial hypertension treated with amlodipine and ace-
tylsalicylic acid, presented in May 2014 with a strong visual loss due to a central RVO (CRVO) 
in his left eye that occurred in 2011 (Fig. 1) and for which he had undergone two intravitreal 
Ozurdex injections in January and October 2013. His medical history revealed a previous 
CRVO also in his right eye, but it was ignored and never subjected to treatment. At the time of 
first examination, his uncorrected visual acuity was hand motion in his right eye and his best 
corrected visual acuity (BCVA) 1 in his left eye. Intraocular pressure was 10 mm Hg in his right 
eye and 16 mm Hg in the left one. Slit lamp examination showed bilateral pseudophakia; di-
lated fundus examination presented bilateral outcomes of CRVO. SD-OCT identified a notable 
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VMT in the left eye characterized by an alteration of the macular profile and an increase of 
central retinal thickness (459 μm) with multiple intraretinal pseudocysts. Interruption of pho-
toreceptor inner segment/outer segment (IS/OS) junctional layer and altered reflectivity and 
morphology of the retinal pigmented epithelium/choriocapillary complex were also evident 
(Fig. 2). In June 2014, the patient received a single 125-μg ocriplasmin intravitreal injection in 
his left eye. Two months later, BCVA was stable, anterior segment was quiet, and dilated fun-
dus examination showed a complete release of VMT. Specifically, OCT scans demonstrated the 
complete release of VMT, characterized by an improvement of the retinal profile with reap-
pearance of the foveal pit and a significant central macular thickness reduction (141 μm). 
Slightly increased paracentral macular thickness persisted, especially nasal to the fovea (285 
μm), although it was remarkably reduced compared to the previous examination. It finally 
showed a slight irregularity of the ILM with small intraretinal pseudocystic spaces and persis-
tent deconstruction of subfoveal IS/OS junctional layer (Fig. 3). In December 2014, the left eye 
remained stable, as revealed by an OCT scan (Fig. 4). 
Discussion and Conclusions 
Ocriplasmin is a promising recombinant protease with activity against fibronectin and 
laminin, components of the vitreoretinal interface. Recently, prospective phase III trials have 
shown their efficacy and safety in the treatment of symptomatic VMA. Particularly, the MIVI-
TRUST program comprised 2 large multicenter, prospective, randomized, placebo-controlled, 
phase III trials (MIVI-006 and MIVI-007) that compared the efficacy of a single 125-μg 
ocriplasmin intravitreal injection (JETREA®) with a single placebo injection for obtaining VMA 
release without vitrectomy [8]. A variety of potential vitreolytic agents have been tested, in-
cluding collagenase, chondroitinase, hyaluronidase, dispase, nattokinase, plasmin, plasmino-
gen activators (tPA and urokinase) and microplasmin [9, 10]. Nevertheless, most of the agents 
examined to date have been abandoned because of toxicity, insufficient clinical efficacy, or 
both. Based on the promising profile reported, ocriplasmin is nowadays the only molecule 
employed. Our case report revealed the importance of the results regarding the anatomic as-
pect of VMT. The complete release of VMT allowed to achieve a relevant morphological im-
provement of the macular area with a decrease in central macular thickness. However, visual 
loss remained stable because of the irreversible degenerative changes of subfoveal IS/OS junc-
tional layer, evaluated by OCT. The improvement in visual acuity is variable and only depends 
on retinal layer integrity. In a prospective trial, where 8 eyes were included using a single 
administration of intravitreal ocriplasmin, 62.5% of patients (5/8 eyes) experienced complete 
release of the VMT. Of the 5 patients with complete release of VMT, 3 patients had a one-line 
worsening of their vision, 1 had a 4-line improvement of vision, and 1 stayed the same. There 
were no complications [11]. Stalmans et al. [8] initially reported a dose- and time-dependent 
cleavage between the posterior hyaloid and the ILM created by ocriplasmin without any ad-
verse effects on retinal structure in both human cadaver and feline eyes. Doses ≥125.0 μg 
(equivalent to 2 units of plasmin) produced a complete PVD with bare ILM in the human eyes, 
as demonstrated by electron microscopy. According to MIVI-TRUST phase III clinical trial 
data, most of ocular adverse events happened during the first week after injection, and the 
most common ones were floaters, ocular pain, visual loss, and phosphenes [8]. However, they 
were less than the risks related to pars plana vitrectomy (PPV), such as infection, bleeding, 
retinal detachment, increase in intraocular pressure, and cataract [12]. Basically, there are 
three alternative treatments for the resolution of a VMT causing a significant visual loss: 
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vitrectomy, pneumatic vitreolysis, and ocriplasmin. Regarding the efficacy and safety profile, 
ocriplasmin is more advantageous than intravitreal injection of perfluoropropane (C3F8) 
(pneumatic vitreolysis) and vitreal surgery, without the concern for the high rate of cataract 
formation seen with PPV [13]. There are currently no published consensus guidelines for the 
management of VMT. However, some general recommendations can be made. Patients should 
be observed for 2–3 months to see if spontaneous resolution occurs, although this is depend-
ent on symptom severity and impact on the individual patient’s quality of life. If there is no 
resolution, treatment with ocriplasmin should be considered, taking into account factors such 
as the width of the VMA, presence of ERM, the status of the affected eye’s lens, and patient age. 
Surgery, as opposed to ocriplasmin, is recommended if significant ERM is present [3]. Positive 
results from trials have made ocriplasmin a promising pharmacologic agent for the treatment 
of symptomatic VMA. Ongoing studies and investigations that should be launched soon will 
certainly help improve those results by specifying the indications, and perhaps broadening 
them as well. Considering its ability to induce PVD, other ophthalmic conditions and patholo-
gies related to VMA might benefit from ocriplasmin intravitreal injection, i.e. DME, ARMD,  
vitreoretinal surgery, uveitic macular edema, pediatric eyes before vitrectomy; nevertheless, 
first results were not as satisfying as the ones achieved in the treatment of VMA [14, 15]. Fur-
ther research is needed to better understand the clinical indications, visual improvement and, 
most of all, potential interactions with other medications. 
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Fig. 1. Fluorescein angiography of the left eye with central retinal vein occlusion showing marked hypo-
fluorescence secondary to widespread capillary nonperfusion. 
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Fig. 2. Left eye SD-OCT performed before ocriplasmin intravitreal injection revealing a remarkable VMT 
characterized by an alteration of the macular profile and an increase in central retinal thickness (459 μm) 
with multiple intraretinal pseudocysts. Interruption of photoreceptor IS/OS junctional layer and altered 
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Fig. 3. Complete release of VMT with significant reduced foveal thickness (141 μm), and reappearance of 
the foveal pit observed with SD-OCT 2 months after (August 2014) ocriplasmin intravitreal injection in the 
left eye. Nasal to the fovea, increased thickness persisted despite a remarkable reduction compared to the 
previous examination (May 2014). 
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Fig. 4. SD-OCT performed in December 2014 demonstrated that the left eye remained stable. 
 
